Thomas R. Webb

Thomas R. Webb

Auto-generated profile, based on publicly available information

Thomas R. Webb

SRI International, Menlo Park, CA

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2013 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CLChandraiah Lagisetti
Chandraiah Lagisetti
GPGustavo Palacios
Gustavo Palacios
TGTinopiwa Goronga
Tinopiwa Goronga
BFBurgess Freeman
Burgess Freeman
WCWilliam Caufield
William Caufield
TWThomas R. Webb
Thomas R. Webb

30 December 2013 in ACS Chemical Biology
Verified
Journal Article
Closed access
CLChandraiah Lagisetti
Chandraiah Lagisetti
MYMaria V. Yermolina
Maria V. Yermolina
LSLalit Kumar Sharma
Lalit Kumar Sharma
GPGustavo Palacios
Gustavo Palacios
BPBrett J. Prigaro
Brett J. Prigaro
TWThomas R. Webb
Thomas R. Webb

14 March 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MSMin-Suk Song
Min-Suk Song
GKGyanendra Kumar
Gyanendra Kumar
WSWilliam R. Shadrick
William R. Shadrick
WZWei Zhou
Wei Zhou
TJTrushar Jeevan
Trushar Jeevan
SWStephen W. White
Stephen W. White
Significance: The endonuclease domain within the influenza virus heterotrimeric replication machinery is essential and represents an attractive drug target. It is important to understand the structural basis of potential inhibitor resistance, to design appropriate inhibitors and to prioritize drug candidates that are unlikely to cause the rapid development of clinically-relevant resistance mutations. Using a prototypical endonuclease inhibitor (L-742,001), we used mutagenesis to select for replication competent resistant mutants and studied the structural and functional basis for the observed resistance. These studies confirm that the endonuclease domain is an excellent drug target for treating influenza. They also provide reagents (mutant viruses and constructs) and crucial pharmacophore knowledge that will aid in the development of new drug candidates for urgently needed influenza therapies.

15 October 2014 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
PMPrema L. Mallipeddi
Prema L. Mallipeddi
GKGyanendra Kumar
Gyanendra Kumar
SWStephen W. White
Stephen W. White
TWThomas R. Webb
Thomas R. Webb
Influenza is a seasonal and serious health threat, and the recent outbreak of H7N9 following the pandemic spread of H1N1 in 2009 has served to emphasize the importance of anti-influenza drug discovery. Zanamivir (Relenza™) and oseltamivir (Tamiflu®) are two antiviral drugs currently recommended by the CDC for treating influenza. Both are examples of the successful application of structure-based drug design strategies. These strategies have combined computer- based approaches, such as docking- and pharmacophore-based virtual screening with X-ray crystallographic structural analyses. Docking is a routinely used computational method to identify potential hits from large compound libraries. This method has evolved from simple rigid docking approaches to flexible docking methods to handle receptor flexibility and to enhance hit rates in virtual screening. Virtual screening approaches can employ both ligand-based and structurebased pharmacophore models depending on the available information. The exponential growth in computing power has increasingly facilitated the application of computer-aided methods in drug discovery, and they now play significant roles in the search for novel therapeutics. An overview of these computational tools is presented in this review, and recent advances and challenges will be discussed. The focus of the review will be anti-influenza drug discovery and how advances in our understanding of viral biology have led to the discovery of novel influenza protein targets. Also discussed will be strategies to circumvent the problem of resistance emerging from rapid mutations that has seriously compromised the efficacy of current anti-influenza therapies.

11 April 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
JTJian Tu
Jian Tu
ZHZijun Huo
Zijun Huo
YYYao Yu
Yao Yu
DZDandan Zhu
Dandan Zhu
AXAn Xu
An Xu
Dung-Fang LeeDung-Fang Lee
Dung-Fang Lee
Significance: Rare human hereditary disorders provide unequivocal evidence of the role of gene mutations in human disease pathogenesis and offer powerful insights into their influence on human disease development. Using a hereditary retinoblastoma (RB) patient–derived induced pluripotent stem cell (iPSC) platform, we elucidate the role of pRB/E2F3a in regulating spliceosomal gene expression. Pharmacological inhibition of the spliceosome in RB1 -mutant cells preferentially increases splicing abnormalities of genes involved in cancer-promoting signaling and impairs cell proliferation and tumorigenesis. Expression of pRB/E2F3a–regulated spliceosomal proteins is negatively associated with pRB expression and correlates with poor clinical outcomes of osteosarcoma (OS) patients. Our findings strongly indicate that the spliceosome is an “Achilles’ heel” of RB1 -mutant OS.

18 December 2014 in Retrovirology
Verified
Journal Article
Open access
PDF file
MTMorgan Thénoz
Morgan Thénoz
CVCéline Vernin
Céline Vernin
HMHussein Mortada
Hussein Mortada
MKMaroun Karam
Maroun Karam
CPChristiane Pinatel
Christiane Pinatel
FMFranck Mortreux
Franck Mortreux
Reprogramming cellular gene transcription sustains HTLV-1 viral persistence that ultimately leads to the development of adult T-cell leukemia/lymphoma (ATLL). We hypothesized that besides these quantitative transcriptional effects, HTLV-1 qualitatively modifies the pattern of cellular gene expression. Exon expression analysis shows that patients’ untransformed and malignant HTLV-1+ CD4+ T-cells exhibit multiple alternate exon usage (AEU) events. These affect either transcriptionally modified or unmodified genes, culminate in ATLL, and unveil new functional pathways involved in cancer and cell cycle. Unsupervised hierarchical clustering of array data permitted to isolate exon expression patterns of 3977 exons that discriminate uninfected, infected, and transformed CD4+ T-cells. Furthermore, untransformed infected CD4+ clones and ATLL samples shared 486 exon modifications distributed in 320 genes, thereby indicating a role of AEUs in HTLV-1 leukemogenesis. Exposing cells to splicing modulators revealed that Sudemycin E reduces cell viability of HTLV-1 transformed cells without affecting primary control CD4+ cells and HTLV-1 negative cell lines, suggesting that the huge excess of AEU might provide news targets for treating ATLL. Taken together, these data reveal that HTLV-1 significantly modifies the structure of cellular transcripts and unmask new putative leukemogenic pathways and possible therapeutic targets.